65,437 trials
Conscious Sedation · Deep Sedation · Critical Care
Primary: Amplitudes (in Micro Volts) of Acoustic Event Related Potentials (Time-locked Amplitudes in the Electroencephalogram 100 Milliseconds After the Acoustic Stimulus…
Neoplasms, Breast
Primary: Overall Tumor Response (OR) — 53 percentage of participants
Orthomyxoviridae Infection · Influenza · Myxovirus Infection
Primary: Geometric Mean Titers (GMTs) Before and Post Vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine — 8.9; 9.6; 20.5; 26.9 Titers
Hypertension
Primary: Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 — 99.2; -12.7 mm Hg — p=<0.05
Abdominal Neoplasm · Colonic Neoplasm · Mesothelioma
Primary: Number of Participants With Disease-free Survival
Influenza, Human
Primary: Time to Alleviation of Influenza Illness — 73.0; 85.8; 73.6 hours — p=0.748
Alzheimer's Disease
Primary: Alzheimer's Disease Assessment Scale-Cognitive Subscale 75 (ADAS-Cog 75) at Week 6 — 18.07; 18.49 units on scale — p=0.3873
Healthy
Primary: Geometric Mean Fold-rise (GMFR) After the Administration of the Lyophilized Formulation of V710 (60 mcg). — 5.3; 1.0 Ratio
Myelodysplastic Syndrome
Primary: Participants Survival Status as of the Time of the Extension Study Follow-up — 101; 29; 18 participants
Asthma
Primary: Fold Increase in ASM Proliferation Following Incubation With Eosinophils. — 2; 2 Fold increase in ASM cell proliferation — p=<0.05
Acute Gout
Primary: Time to First New Flare — NA; NA Days
Hepatitis C, Chronic · Hepatitis C
Primary: Number of Participants Who Are Triple-80 Compliant — 183 Participants
Asthma
Primary: Post-dose PC20 — 7; 16 mg/mL
Influenza
Primary: Number of Participants in the CD4 Less Than 200/mL Stratum With 4-Fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza…
End Stage Renal Disease
Primary: High Sensitivity C-reactive Protein (hsCRP) — 4.67; 15.11 mg/dl — p=0.008